

SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.


Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
"You can't just redefine how you calculate percentages," said one mathematician in response to Kennedy's claims.
US Health and Human Services Secretary Robert F. Kennedy Jr. on Wednesday tried to defend President Donald Trump's mathematically absurd claims about prescription drug prices by saying the president has his own unique method of calculating percentages.
During a Senate Finance Committee hearing, Sen. Elizabeth Warren (D-Mass.) grilled Kennedy about the president's repeated false claims that he has slashed the prices of prescription drugs by as much as 600%, which would mean that pharmaceutical companies are paying consumers to take their medications.
"President Trump has his own way of calculating," Kennedy replied. "There's two ways of calculating percentages. If you have a $600 drug, and you reduce it to $10, that's a 600% reduction."
RFK Jr: "President Trump has a different way of calculating percentages. If you have a $600 drug and you reduce it to $10, that's a 600% reduction." pic.twitter.com/MjDNADqc8p
— Aaron Rupar (@atrupar) April 22, 2026
In fact, such a drop in price would represent a 98.3% reduction, less than one-sixth the size of the president's claims. A 600% reduction in the price of a $600 drug would mean that drug manufacturer paid consumers $3,000 every time they picked up their prescription.
Kit Yates, a mathematician at the University of Bath, marveled at Kennedy's attempts to create an alternate version of arithmetic.
"We've known for a while that the USA's current regime have been out for science, but I never thought they would try to mess with math!" Yates wrote in a social media post. "You can't just redefine how you calculate percentages."
In addition to exposing Kennedy's apparent ignorance of elementary mathematics, Warren shined a light on how the TrumpRx website misleads consumers into thinking they're being offered bargains on prescription drugs that are available elsewhere in generic varieties.
In once instance, Warren noted that TrumpRx is selling a brand-name heartburn medication for $200, whereas a generic version of the same drug is available at Costco for $16. Warren also highlighted a heart arrhythmia drug for sale on TrumpRx for $336, even though a generic version of the drug is available at Costco for $12.
Warren added that, in exchange for making select brand-name drugs available on the TrumpRx website, pharmaceutical companies have gotten exemptions from the president's 100% tariffs on imported patented medicines.
"Think about that: Big Pharma makes billions of dollars in tariff relief by listing their drugs on TrumpRx, and then they don't even lower the costs on many of these drugs," she said. "That is a great deal for Big Pharma."
Warren's analysis of TrumpRx's pricing scheme echoes a March report from the Center for American Progress (CAP), which found that the president's prescription drug website offered genuinely lower prices on “exactly one” of the 54 medications listed.
CAP also found that nearly one-third of the drugs available on the TrumpRx website have generic alternatives that were cheaper than what was being offered, and that the website made no mention of this.
Reuters reported in December that at least 350 branded medications are set for price hikes in 2026, including “vaccines against Covid, RSV, and shingles,” as well as the “blockbuster cancer treatment Ibrance.”
Later in the Senate Finance Committee hearing, Sen. Bernie Sanders (I-Vt.) ridiculed Kennedy for claiming that, under Trump's leadership, "the American people are now paying the lowest costs in the world rather than the highest for prescription drugs."
"That is an absurd statement," Sanders said. "Nobody in the world believes that."
"As they continue to hike prices, the pharmaceutical industry is also working overtime to block reforms that would lower them, and patients are paying the price."
A report released Monday found that Big Pharma has continued raising prices on dozens of cancer drugs, despite President Donald Trump's repeated false claims that he and his administration have slashed drug prices by a mathematically impossible 600%.
The analysis, conducted by Patients for Affordable Drugs, found that pharmaceutical companies increased prices on 64 oncology drugs in the first weeks of 2026, with the vast majority of price hikes coming in above the rate of inflation.
Patients for Affordable Drugs noted the heavy financial toll that paying for treatments takes on US cancer patients, and said the latest price increases would only exacerbate the crisis.
"Cancer drugs are among the most expensive drugs on the market, costing $74,000 more on average than non-cancer drugs," the group explained. "More than 42% of cancer patients in the US fully depleted their savings within two years of diagnosis to cover their care. More than half of Americans with cancer go into debt because of the cost of their care."
Making matters worse, the group added, is that Big Pharma is heavily lobbying Congress to pass legislation that would further delay small molecule drugs, including "widely used, high-cost cancer treatments," from becoming eligible for Medicare price negotiations.
Merith Basey, CEO of Patients for Affordable Drugs, stressed that the latest price increases were unacceptable given that "cancer is a leading cause of death among American seniors, and the treatments patients rely on are already among the most expensive."
"Yet as they continue to hike prices, the pharmaceutical industry is also working overtime to block reforms that would lower them," added Basey, "and patients are paying the price."
While the Patients for Affordable Drugs report focuses on cancer drugs, a December report from Reuters found that at least 350 branded medications are set for price hikes in 2026, including “vaccines against Covid, RSV, and shingles,” as well as the “blockbuster cancer treatment Ibrance.”
The total projected number of drugs seeing price increases in 2026 is significantly higher than in 2025, when 3 Axis Advisors estimated that pharmaceutical companies raised prices on 250 medications. The median price increase for drugs in 2026 is projected at 4%, roughly the same as in 2025.
All of these price increases have come despite Trump's false claims that he has lowered the prices of drugs to the point where pharmaceutical companies would actually be paying patients to take them.
An analysis released last week by the Center for American Progress (CAP) found that the president's TrumpRx initiative, which was created to purportedly offer Americans cheaper prescription drugs, offered genuinely lower prices on "exactly one" of the 54 medications listed on its website.
CAP also found that nearly one-third of the drugs available on the TrumpRx website have generic alternatives that were cheaper than what was being offered, and that the website made no mention of this.
"For the 22 million Americans whose premiums have doubled, and the millions more who stand to lose coverage, a $56 discount on a fertility drug is not 'immediate relief.'"
US President Donald Trump launched TrumpRx last month with a bold promise to the American public: "dramatically lower prices on dozens of common, high-cost, brand-name prescription drugs."
But an analysis released Tuesday by the Center for American Progress (CAP) found that of the 54 medications listed on TrumpRx.gov as of March 16, "exactly one" drug—the fertility medication Cetrotide—is available at a "genuinely new lower price" not available elsewhere.
The CAP analysis emphasized that TrumpRx—touted by the administration as a path to "immediate relief" for consumers in the country with the highest drug prices in the world—is extremely limited by design, listing just 0.2% of all federally approved medications in the US.
Additionally, the terms that site users must accept before gaining access to coupons for discounted prices state that beneficiaries cannot be "enrolled in insurance from any government, state, or federally funded medical or prescription benefit programs."
Patients also must have a prescription to use TrumpRx for discounts. "According to a KFF analysis," CAP noted, "nearly half (46.6%) of uninsured adults ages 18 to 64 reported not seeing a doctor or other health professional in 2023."
"Applied to the estimated 27.9 million adults without insurance in 2026, this means that approximately 13 million Americans will never reach the most basic prerequisite for using TrumpRx: a visit with a clinician who can write a prescription," CAP added.
The think tank's analysis found that 17 of the drugs on TrumpRx—or over 30% of them—have generic equivalents that are available at a lower cost elsewhere, something that the Trump-branded platform doesn't tell users.
"Among the remaining 37 drugs without lower-cost generics, GoodRx offers comparable or lower prices for 20," CAP found. "That leaves 17 drugs where TrumpRx appears to offer a better deal. But in 16 of those cases, the same or lower prices were already available through manufacturer coupons and patient assistance programs. After accounting for all existing discount channels, just one drug—Cetrotide, a fertility medication—offers a price that was not previously available to cash-paying patients."
Neda Ashtari, associate director of health policy at CAP and author of the new analysis, said in a statement that the Trump administration is "undermining the most powerful tool for lowering patients’ costs at the pharmacy counter—health insurance coverage—and replacing it with a government-branded coupon book."
“For the 22 million Americans whose premiums have doubled, and the millions more who stand to lose coverage," due to Trump and the GOP's refusal to extend enhanced Affordable Care Act subsidies, "a $56 discount on a fertility drug is not 'immediate relief,'" Ashtari added.
CAP's analysis was released a day before The New York Times and the German news organizations Süddeutsche Zeitung, NDR, and WDR debunked Trump's claim last month to have delivered the lowest drug prices "in the entire world"—which would be news to the 1 in 3 US adults who say they've rationed medications, skipped meals, or made other painful tradeoffs over the past year to afford healthcare expenses.
"The drugs listed on TrumpRx can cost American patients up to hundreds or thousands of dollars, while a patient walking into a German pharmacy pays next to nothing," the Times observed on Wednesday. "The German health system foots the bill, and records show that, more often than not, it pays less than what the Trump administration negotiated for Americans."